Headlands Technologies LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 72,335 shares of the company’s stock, valued at approximately $1,546,000.
Separately, Aristeia Capital L.L.C. purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $397,000.
NewAmsterdam Pharma Stock Down 1.3%
NewAmsterdam Pharma stock opened at $16.30 on Tuesday. The company has a 50 day moving average price of $19.25 and a 200-day moving average price of $21.02. NewAmsterdam Pharma has a fifty-two week low of $12.67 and a fifty-two week high of $30.45.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding NAMSW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report).
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
